azomycin has been researched along with Black Fever in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braillard, S; Chatelain, E; Cooper, CB; Denny, WA; Franzblau, SG; Gupta, S; Launay, D; Ma, Z; Maes, L; Marshall, AJ; O'Connor, PD; Thompson, AM; Wan, B; Wang, Y; Yardley, V | 1 |
| De Rycker, M; Fairlamb, AH; Norval, S; Osuna-Cabello, M; Patterson, S; Perry, MR; Read, KD; Simeons, FR; Stojanovski, L; Wyllie, S | 1 |
| Gupta, S; Launay, D; Martin, D; Puri, SK; Sharma, B; Shivahare, R; Vishwakarma, P; Yardley, V | 1 |
| Auer, JL; Fairlamb, AH; Norval, S; Osuna-Cabello, M; Patterson, S; Read, KD; Simeons, FR; Stojanovski, L; Wyllie, S | 1 |
| Fairlamb, AH; Kime, R; Norval, S; Patterson, S; Read, KD; Simeons, FR; Stojanovski, L; Wyllie, S | 1 |
| Fairlamb, AH; Patterson, S; Wyllie, S | 1 |
6 other study(ies) available for azomycin and Black Fever
| Article | Year |
|---|---|
7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Cricetinae; Drug Discovery; Female; Humans; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Male; Mesocricetus; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazines; Rats, Sprague-Dawley | 2017 |
The R enantiomer of the antitubercular drug PA-824 as a potential oral treatment for visceral Leishmaniasis.
Topics: Animals; Antiprotozoal Agents; Antitubercular Agents; Female; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Nitroimidazoles; Stereoisomerism | 2013 |
Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Cricetinae; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Compounding; Drug Evaluation, Preclinical; Female; Humans; Inhibitory Concentration 50; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Nitric Oxide; Nitric Oxide Synthase Type II; Nitroimidazoles; Parasitic Sensitivity Tests; Time Factors | 2015 |
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Antitubercular Agents; Biotransformation; Disease Models, Animal; Drug Administration Schedule; Drug Dosage Calculations; Drug Repositioning; Female; Hormesis; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazoles; Parasitic Sensitivity Tests; Treatment Outcome | 2016 |
The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.
Topics: Administration, Oral; Animals; Biotransformation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Leishmania donovani; Leishmaniasis, Visceral; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Nitroimidazoles; Nitroreductases; Parasitic Sensitivity Tests; Protozoan Proteins; Sulfones; Sulfoxides; Trypanocidal Agents | 2012 |
Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.
Topics: Cell Line; Drug Resistance; Gene Knockout Techniques; Leishmania donovani; Leishmaniasis, Visceral; Nitro Compounds; Nitroimidazoles; Nitroreductases; Trypanocidal Agents | 2013 |